Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Submitted by
admin
on June 5, 2010 - 12:24pm
Source:
BusinessWire
News Tags:
chronic myeloid leukemia
Sprycel
dasatinib
Gleevac
BMS
Otsuka
Headline:
SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Do Not Allow Advertisers to Use My Personal information
